ATE399562T1 - Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen - Google Patents

Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen

Info

Publication number
ATE399562T1
ATE399562T1 AT02796345T AT02796345T ATE399562T1 AT E399562 T1 ATE399562 T1 AT E399562T1 AT 02796345 T AT02796345 T AT 02796345T AT 02796345 T AT02796345 T AT 02796345T AT E399562 T1 ATE399562 T1 AT E399562T1
Authority
AT
Austria
Prior art keywords
mixture
microbial
prophylaxis
treatment
virus infections
Prior art date
Application number
AT02796345T
Other languages
English (en)
Inventor
Michael Folan
Damien Brady
Original Assignee
Westgate Biolog Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westgate Biolog Ltd filed Critical Westgate Biolog Ltd
Application granted granted Critical
Publication of ATE399562T1 publication Critical patent/ATE399562T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02796345T 2001-08-23 2002-08-20 Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen ATE399562T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IES20010780 2001-08-23

Publications (1)

Publication Number Publication Date
ATE399562T1 true ATE399562T1 (de) 2008-07-15

Family

ID=11042830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796345T ATE399562T1 (de) 2001-08-23 2002-08-20 Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen

Country Status (15)

Country Link
US (2) US7687074B2 (de)
EP (1) EP1427436B1 (de)
JP (1) JP4532900B2 (de)
KR (1) KR100907959B1 (de)
CN (1) CN1578670B (de)
AT (1) ATE399562T1 (de)
AU (1) AU2002356112B2 (de)
CA (1) CA2458146C (de)
DE (1) DE60227389D1 (de)
DK (1) DK1427436T3 (de)
ES (1) ES2309228T3 (de)
NZ (1) NZ531639A (de)
PT (1) PT1427436E (de)
RU (1) RU2305547C2 (de)
WO (1) WO2003018049A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863168A1 (fr) * 2003-12-04 2005-06-10 Centre Nat Rech Scient Utilisation d'inducteurs de la voie de degradation de la gamma-butyrolactone pour inactiver le signal n-acy homoserine lactone.
AU2005262392A1 (en) * 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
WO2007035870A2 (en) * 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
WO2007061942A2 (en) 2005-11-18 2007-05-31 Glanbia Nutritionals (Ireland) Ltd. Compositions for disrupting and inhibiting reconstitution of wound biofilm
JP5017531B2 (ja) * 2006-09-11 2012-09-05 株式会社アップウェル 口内清浄剤
US20100317734A1 (en) * 2007-12-04 2010-12-16 Michael Anthony Folan Free fatty acid blends and use thereof
JP2009190994A (ja) * 2008-02-13 2009-08-27 Kitasato Institute 抗インフルエンザウイルス剤、及びその有効成分の製造方法
US20090311236A1 (en) * 2008-06-11 2009-12-17 Immune @Work, Inc. Therapeutic Peptide Compositions And Methods Of Making And Using Same
CA2727223C (en) * 2008-06-11 2014-10-07 Ricom Corporation Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
US8808345B2 (en) * 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
WO2010082587A1 (ja) * 2009-01-13 2010-07-22 株式会社大気倶楽部 空中懸濁物吸着剤
KR101119538B1 (ko) * 2009-06-10 2012-02-22 장선호 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방 및 치료용 조성물
ES2643862T3 (es) * 2009-11-17 2017-11-24 Michael Anthony Folan Composiciones antimicrobianas que contienen ácidos grasos libres
UY33548A (es) * 2010-08-06 2012-02-29 Eurand Pharmaceuticals Inc Formula nutricional predigerida
KR101355018B1 (ko) * 2010-12-13 2014-01-24 노부오 구보 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방용 동물사료 첨가제 및 이를 포함하는 동물사료용 조성물
RU2494726C2 (ru) * 2011-04-11 2013-10-10 Общество с Ограниченной Ответственностью "Производственная Торговая Компания "Лактив" Способ профилактики и лечения грибковой инфекции у больных с голосовыми протезами
EP3150257A1 (de) * 2015-09-30 2017-04-05 Buga, Doris Verfahren zur herstellung einer zusammensetzung zur stärkung des immunsystems
CA3026402A1 (en) 2017-12-05 2019-06-05 James F. Kane Water-soluble cannabinoids and methods of making same
US11298379B2 (en) * 2020-04-16 2022-04-12 James F. Kane Compositions comprising milk fat globules and methods of making same
CN113855787A (zh) * 2020-06-30 2021-12-31 北京大学 乳清蛋白作为冠状病毒广谱抑制剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2796378A (en) * 1954-04-09 1957-06-18 Jr Edgar A Ferguson Methionine free reaction product of a water-soluble copper salt and lactalbumin hydrolysate as fungicide
GB1050756A (de) * 1964-09-10 1900-01-01
US4397927A (en) * 1982-03-25 1983-08-09 Brog Roy A Imitation milk compositions and aqueous dispersions prepared therefrom
US4918008A (en) * 1985-01-18 1990-04-17 Gauri Kailash Kumar Process for the preparation of protein hydrolysate and medicaments containing these hydrolysates
JPS62249931A (ja) * 1986-04-21 1987-10-30 Morinaga Milk Ind Co Ltd 抗菌性組成物
JPH085798B2 (ja) 1987-02-02 1996-01-24 紀夫 多田 抗菌剤
ES2043279T3 (es) * 1989-06-07 1993-12-16 Kao Corp Emulsion comestible de aceite en agua.
JP2673320B2 (ja) 1990-01-25 1997-11-05 雪印乳業株式会社 う蝕原菌付着阻止剤
JPH04159232A (ja) 1990-08-21 1992-06-02 Yakult Honsha Co Ltd 日和見感染症予防・治療用経口組成物
CA2094570A1 (en) * 1992-05-27 1993-11-28 Jerome F. Trumbetas Enzymatic protein process and product
CA2148261A1 (en) 1992-10-30 1994-05-11 Jerry A. Peterson Anti-diarrheic product and method of treating rotavirus-associated infection
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
AU7792294A (en) * 1994-08-16 1996-03-07 Hemant Sabharwal Antibacterial composition containing multimeric alpha-lactalbumin
JP4233615B2 (ja) 1996-08-22 2009-03-04 森永乳業株式会社 経口抗ヒト爪白癬及び／又は爪白癬以外のヒト足部白癬用医薬品
WO1998030235A1 (en) * 1997-01-09 1998-07-16 Morinaga Milk Industry Co., Ltd. Lactoferrin tablets
IE970541A1 (en) 1997-07-25 1999-01-27 Michael Anthony Folan Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity
JP4129566B2 (ja) * 1997-09-05 2008-08-06 大塚製薬株式会社 肝臓脂肪蓄積抑制組成物及び肝臓脂肪蓄積抑制用食品添加剤
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US6126955A (en) * 1998-04-16 2000-10-03 University Of Utah Research Foundation Apo-transferrin as a potent inhibitor of bacterial adhesion to biomaterials
CA2332127A1 (en) * 1998-06-26 2000-01-06 N.V. Nutricia Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
GB9903584D0 (en) 1999-02-18 1999-04-07 Univ Leeds Modified calycins
JP3662445B2 (ja) * 1999-06-30 2005-06-22 花王株式会社 油中水型乳化油脂組成物
EP1395124B1 (de) * 2001-05-23 2006-04-12 Nutricopia, Inc. Gefrorene ernährungssüssspeisen und verfahren zu ihrer herstellung
US20030165606A1 (en) 2001-07-18 2003-09-04 Lasekan John B. Anti-regurgitation formula and uses thereof
EP1319407A1 (de) * 2001-12-14 2003-06-18 Montoie Import-Export S.A. Arzneimittel zur lokalen Behandlung von Hauterkrankungen und Hautwunden

Also Published As

Publication number Publication date
WO2003018049A3 (en) 2003-11-06
ES2309228T3 (es) 2008-12-16
US7972629B2 (en) 2011-07-05
NZ531639A (en) 2006-02-24
JP4532900B2 (ja) 2010-08-25
US7687074B2 (en) 2010-03-30
RU2305547C2 (ru) 2007-09-10
KR100907959B1 (ko) 2009-07-16
CA2458146A1 (en) 2003-03-06
JP2005501863A (ja) 2005-01-20
CN1578670B (zh) 2013-09-04
DK1427436T3 (da) 2008-10-13
RU2004108040A (ru) 2005-09-27
AU2002356112B2 (en) 2007-11-08
DE60227389D1 (de) 2008-08-14
CN1578670A (zh) 2005-02-09
US20050042299A1 (en) 2005-02-24
CA2458146C (en) 2012-07-24
EP1427436A2 (de) 2004-06-16
PT1427436E (pt) 2008-09-08
KR20040041579A (ko) 2004-05-17
EP1427436B1 (de) 2008-07-02
WO2003018049A2 (en) 2003-03-06
US20100209526A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
DE60227389D1 (de) Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
US20110020279A1 (en) Rabies cure
Almeida et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials
Ghosh et al. Management of snake bite in India
US20090130082A1 (en) Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
JP2804979B2 (ja) エイズ治療および阻害剤
WO2025117451A1 (en) Therapeutic use of fibroblasts to treat the common cold
Baba et al. Resolution of cutaneous lesions of granuloma annulare by intralesional injection of human fibroblast interferon
CN114712355A (zh) Rhps4在制备抑制人类病原菌药物中的应用及其药物
Hamad Minocycline superior to chloroquine phosphate as COVID-19 treatment
Sokolov et al. Contaminated problematic skin wounds in diabetic patients treated with autologous platelet-rich plasma (PRP): a case series study
RU2188665C1 (ru) Противовирусное и антибактериальное средство "интерлизин"
US20140329780A1 (en) Inhibitor of colonisation of mucosa
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
AP1629A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes.
Waghchaure et al. A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT
RU2674445C1 (ru) Спрей для наружного применения спиртовой
RU2180532C2 (ru) Способ лечения папилломатоза
RU1782597C (ru) Способ профилактики некроза кожного лоскута на питательной ножке
WO2012070967A1 (ru) Ранозаживляющая, противоожоговая, регенерирующая и противовирусная фармацевтическая композиция для местного применения
Roberts Antifibrinolytic agents in traumatic hemorrhage

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427436

Country of ref document: EP